Delta Sleep-Inducing Peptide. Nine-amino acid neuropeptide modulating slow-wave sleep architecture.
Evidence is experimental. Most claims trace to limited human studies or animal models. Treat as a research direction, not a protocol.
Discovered in rabbit cerebral venous blood during sleep induction. Older Soviet/Eastern European clinical work explored use for insomnia, alcohol withdrawal, stress. Mechanism remains poorly characterized; receptor not definitively identified. Modern Western evidence is thin.
Decades-old molecule with thin modern evidence. Subjective sleep effects reported but objective polysomnographic data is mixed. Counterfeit risk in grey-market sources.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 100-300 µg · before sleep, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
FDA Cat. 2 removed Apr 2026 — PCAC review Jul 23-24, 2026
FDA's Pharmacy Compounding Advisory Committee scheduled to review the first cohort of peptides removed from Category 2 in April 2026. The 7 peptides on this docket are the highest-profile community names — BPC-157, TB-500, MOTS-c, Epitalon, DSIP, Semax, KPV.
FDA published a Federal Register notice on April 15 2026 removing 12 peptides from the Category 2 ('significant safety concerns') compounding list, paving the way for PCAC review for inclusion on the 503A bulks list. Peptides removed: BPC-157, TB-500, Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, MK-677, Melanotan II, KPV, Semax, LL-37.
FDA's Pharmacy Compounding Advisory Committee categorized a wide list of peptides as Category 2 ('significant safety concerns'), effectively banning their compounding at 503A and 503B pharmacies. Affected: BPC-157, TB-500, Epitalon, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, Selank, LL-37 and others.